Dual specificity antibodies and methods of making and using
    5.
    发明授权
    Dual specificity antibodies and methods of making and using 有权
    双重特异性抗体及其制备和使用方法

    公开(公告)号:US07491516B2

    公开(公告)日:2009-02-17

    申请号:US09894550

    申请日:2001-06-28

    摘要: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-1β ) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental.

    摘要翻译: 提供了对两种不同但结构相关抗原具有双重特异性的抗体。 抗体可以是例如完全是人抗体,重组抗体或单克隆抗体。 优选的抗体对IL-1α和IL-1β具有双重特异性,并在体外和体内中和IL-1α和IL-1β活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测两种不同但结构相关的抗原(例如IL-1α和IL-1β),并且用于抑制抗原的活性,例如在患有疾病的人类受试者中 其中IL-1α和/或IL-1β活性是有害的。

    Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
    6.
    发明申请
    Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof 审中-公开
    内皮素受体拮抗剂与磷酸二酯酶5抑制剂的组合及其用途

    公开(公告)号:US20060205733A1

    公开(公告)日:2006-09-14

    申请号:US11211099

    申请日:2005-08-25

    摘要: The invention relates generally to combination therapies comprising an endothelin A receptor (ETA) antagonist and a phosphodiesterase 5 (PDE5) inhibitor, pharmaceutical compositions comprising ETA antagonist and PDE5 inhibitor and methods of treating various disorders comprising administering an ETA antagonist and a PDE5 inhibitor. In particular, the combination therapies and pharmaceutical compositions are useful for the treatment and/or prevention of cardiac disorders such as pulmonary arterial hypertension (PAH).

    摘要翻译: 本发明一般涉及包含内皮素A受体(ETA)拮抗剂和磷酸二酯酶5(PDE5)抑制剂的组合疗法,包含ETA拮抗剂和PDE5抑制剂的药物组合物和 治疗各种疾病的方法包括施用ETA拮抗剂和PDE5抑制剂。 特别地,组合疗法和药物组合物可用于治疗和/或预防心脏疾病如肺动脉高压(PAH)。

    Plant fatty acid amide hydrolases
    10.
    发明申请
    Plant fatty acid amide hydrolases 失效
    植物脂肪酸酰胺水解酶

    公开(公告)号:US20050028233A1

    公开(公告)日:2005-02-03

    申请号:US10862063

    申请日:2004-06-04

    摘要: The invention provides plant fatty acid amide hydrolase (FAAH) coding sequences. Also provided are constructs comprising these sequences, plants transformed therewith and methods of use thereof. The invention allows the modification of plants for FAAH activity and N-Acylethanolamine levels. Such modification may be used to produce plants that are improved with respect to growth, seed germination, pathogen response and stress tolerance.

    摘要翻译: 本发明提供植物脂肪酸酰胺水解酶(FAAH)编码序列。 还提供了包含这些序列的构建体,用其转化的植物及其使用方法。 本发明允许植物修饰FAAH活性和N-亚苄醇胺水平。 这种修饰可用于产生相对于生长,种子发芽,病原体应答和胁迫耐受性改进的植物。